José Valentín López

UPR Cayey ‘19 Chemistry | M3 @ University of Minnesota MSTP (MD-PhD) | Future Pathologist 🔬

[José Valentín López @JValentinLopez]

Headed to #USCAP2026 for a couple of days of great science, insightful discussions, and connecting with future colleagues in pathology!

See you all there!

@TheUSCAP
#PathX

[José Valentín López @JValentinLopez]

#AACR25

[Emmanuel Antonarakis @EAntonarakis]

Analysis of B7-H3 in >150,000 cancer samples from >50 histologies. A new therapeutic target is born. Congrats to Carly Miller on her first-author paper. Thanks also to @CarisLife for their collaboration. https://t.co/mtp9zan0jm

[José Valentín López @JValentinLopez]

Great discussions happening at the 2024 GRS and GRC on Lipidomics!

[José Valentín López @JValentinLopez]

Its out! Check out our latest review article “Androgen receptor and estrogen receptor variants in prostate and breast cancers” in the Journal of Steroid Biochemistry and Molecular Biology 🧫 🧬

https://t.co/VUO7TlEnyJ

[Haynes Group @HaynesChemLab]

@UMNChemistry’s summer intramural softball was back after a Covid-hiatus!

Congrats to The Dynamic Scatterers for taking 3rd place! 🙌🏽✨💪🏽

@TLOkeefe12 @RealMMA10 @W_AlvarezReyes @Finetraces786 @caseyh2os + lots of friends!

[Sumanta K. Pal, MD, FASCO @montypal]

Wonderful presentation by @AlbigesL @GustaveRoussy arguing for doublet v triplet tx. Slides updated to reflect data from @brian_rini @VUMCDiscoveries & @DrTHut @TheUSONetwork presented at #ASCO23 just yesterday (wow!). Come join us in Room E451!

[Sam Brondfield, MD, MAEd, FASCO @s_brond]

Thx to 🌟@OncMedEdCoP team for creating a home for anyone interested in #OncMedEd. ✨All✨ are welcome regardless of profession, training, specialty, or @ASCO membership.

Special thx to @JenSchwartzIUSM and @doctormb1 for our #ASCO23 events!

Join us: https://t.co/t4QH5URnuu

[José Valentín López @JValentinLopez]

Thank you again @ConquerCancerFd for the Annual Meeting Research Award!

#ASCO23 #ConquerCancer

[José Valentín López @JValentinLopez]

#ASCO23 Day 4: Prioritizing and Sequencing Therapy for Advanced Prostate Cancer

[Gladys Rodriguez,MD, FASCO @RodriguezGIMD]

Thanks for sharing such an important point! There are so many side-effects that are not seeing! #LCSM #ASCO23

[Yüksel Ürün @DrYukselUrun]

PROSPECT:Can we omit RT in selected patients?
☢️Preoperative Chemotherapy with Selective Chemoradiation versus Chemoradiation for Locally Advanced Rectal Cancer:
☢️Yes! There are no differences regarding DFS, OS, pCR, and locoregional reoccurrence!
@asco @oncoalert #ASCO23

[TwoOncDocs @TwoOncDocs]

#ASCO23 Plenary session underway with results of the PROSPECT trial

🎗️Compared neoadjuvant CRT vs FOLFOX
🎗️ Non-inferiority DFS was met
🎗️Path CR and QOL similar
🎗️Neoadjuvant FOLFOX, with selective use CRT, is an effective tx for pts with CT2N+, cT3N-, or cT3N+ rectal cancer

[José Valentín López @JValentinLopez]

Its time for the #ASCO23 Plenary Session!

[José Valentín López @JValentinLopez]

Very interesting session on Patient-Centric Clinical Trial Design in GU Cancers happening now at #ASCO23

[José Valentín López @JValentinLopez]

It’s time for the 2023 Medical Student & Resident Abstract Forum.

Come check out my poster (22) in S103.

#ASCO23 @LatinxOncology

[José Valentín López @JValentinLopez]

“PSMA PET will become the new gold standard for imaging of prostate cancer”

GU Poster discussion session @ASCO

#ASCO23

[Tom Powles @tompowles1]

ASCO 23 GU cancer highlight @ChrisSweens1 @brian_rini CONTACT-3, THOR, PEACE1, 5 yr KN426 and much more. https://t.co/6ZW36hmDXq

[José Valentín López @JValentinLopez]

Getting ready for #ASCO23 day 2 with a 10K run by Lake Michigan.

[José Valentín López @JValentinLopez]

It does!

@ConquerCancerFd @ASCO #ASCO23